Asssigment

5

Atrial Fibrillation and Portable ECG in Diagnosis and Monitoring

Name of Student

Lecturer Name

Course

Date

Atrial Fibrillation and Portable ECG in Diagnosis and Monitoring

Introduction

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, affects millions of people and is an important cause of morbidity and mortality. The adult population, particularly those over 65, faces an increasing prevalence of AF due to aging, comorbidities, and lifestyle factors. AF increases the risk of stroke, heart failure and additional cardiovascular complications greatly and early detection of AF is imperative in reducing its risk. AF also carries a significant health and economic burden for other than individual health. For the sake of the improvement of patient outcomes, effective diagnosis and a continuous monitoring have to be achieved and that is achievable through the use of the technology such as the portable electrocardiogram (ECG) devices. This paper describes the global AF burden, AF clinical presentation and the paradigm shift in healthcare technology enabled by the advent of portable ECG devices assessing their impact on patient outcomes.

Global Burden of Disease Condition

Atrial fibrillation is a growing public health issue with increasing worldwide prevalence and incidence. AF affects over 46 million people worldwide according to the Global Burden of Disease study, and it is projected to increase with aging and prevalence of risk factors (Kornej et al., 2020). It is estimated that, in the US alone, the number of people who have AF will be 12.1 million by 2030 (CDC, 2024). AF is more likely to develop in older individuals with 6.4% prevalence at age 65–69 and 28.5% in those above 85 years (Khurshid et al., 2023). Additionally, AF is associated with increased healthcare utilization in the form of increased rates of hospitalization, emergency room visits, and an increased risk of ischemic stroke (Joglar et al., 2023).

AF has a wide range of clinical presentation from asymptomatic to severe with palpitations, dyspnea, fatigue, dizziness, chest pain (CDC, 2024). Most episodes are paroxysmal, many of which are not detected and so are missed or delayed diagnosis leading to an enhanced risk of complication thromboembolism. However, intermittent, often asymptomatic presentations often require prolonged rhythm monitoring that places it as the gold standard for diagnosis. According to current guidelines, stroke risk stratification should use the CHA2DS2-VASc score and anticoagulation therapy for high risk patients (Joglar et al., 2023). Treatment options include rate and rhythm control with medications including beta blockers, electrical cardioversion and catheter ablation, and lifestyle modifications. However, there is a lack of timely and effective monitoring; and technological innovation is needed to facilitate improved detection and management of the disease.

Technology and Healthcare

The introduction of digital health technologies has shaped the healthcare in a great way. Portable ECG devices are great examples of the shift toward patient centered care as they enable real time monitoring, early detection and improved disease management. Because the devices are so capable of detecting AF outside of traditional clinical settings, patients with intermittent arrhythmias who would otherwise go undiagnosed are of particular relevance (Brandes et al., 2022). This aligns with the broader movement of digital medicine through the shift towards wearable and mobile health technologies which allow for continuous monitoring for the purposes of developing personalized treatment plans and proactive interventions.

There are a number of benefits of integrating portable ECGs into clinical practice, such as increased diagnostic yield, improved patient engagement, and possible cost savings from decreased hospitalizations and emergency visits (Aljuaid et al., 2020). However, there remains doubt about the accuracy, reliability and interpretation of consumer-driven ECG readings from the public. While some AF studies have reported high sensitivity and specificity in detecting AF, challenges including false positives, the need for physician confirmation, and integration with electronic health records remain (Brandes et al., 2022). Complicating further widespread adoption are regulatory oversight, data privacy concerns, as well as disparities in access to technology. However, portable ECGs are increasingly used as an important asset of AF management, along with traditional diagnostic techniques and to improve patient outcomes.

Chosen Evidence-Based Technology Use in Disease

Portable ECG devices have shown a great deal of potential for improving detection and monitoring of AF. Real time rhythm assessment ECG devices incorporate single or multi lead ECG technology with incorporated smartphone apps. Research have indicated that the portable ECGs, like KardiaMobile and Apple Watch, have high sensitivity (96%) and specificity (92%) in detecting AF (Pearson 2022). The devices enable on demand ECG recording whereby patients can record arrhythmic episodes when they happen for improved diagnostic accuracy compared to regular intermittent monitoring.

Portable ECG use has been linked to better clinical outcomes including fewer emergency department visits and hospitalizations. Aljuaid et al. (2020) found that patients using smartphone based ECG monitor in comparison to the patients relying on traditional event monitor have significantly fewer clinic visits and emergency room admissions. In addition, the ability to perform continuous remote monitoring allows for timely correction of anticoagulation and antirrythmic therapy and eliminates the risk of stroke and of complications of AF (Joglar et al., 2023). Portable ECG technology is thus transformative: its ability to enable real-time data, that leads to the potential to intervene early and with personalized treatment, is a major advance in this area.

Despite these advantages, limitations exist. This could lead to unnecessary anxiety and excessive healthcare utilization through false positives. Workflow difficulties in clinical practice arise from the need for physician confirmation of automated interpretations. Further, there may be cost and accessibility issues that impact widespread adoption, especially with socioeconomically disadvantaged populations (Brandes et al., 2022). In order to address these barriers, healthcare providers, technology developers and policymakers must work together to ensure that implementation is optimized and benefits are maximized.

Conclusion

Atrial fibrillation is a major source of global health burden, and particularly so among the aging adult population. The ability to detect and monitor continuously is crucial for reducing complications and enhancing patient outcomes. AF diagnosis and management has been contributed by portable ECG technology, a useful tool for real-time rhythm assessment, early detection and remote monitoring. These devices provide great advantages but these devices still have to address challenges of accuracy, integration into clinical workflows and accessibility. In the coming years, the future of arrhythmia care will be shaped in large part by the continued advancement of digital health technologies and their incorporation into guideline based AF management. By combining portables ECGs with the standard monitoring approach, AF detection can be further improved, optimal treatment can be achieved, and disease burden can be reduced.

References

Aljuaid, M., Marashly, Q., AlDanaf, J., Tawhari, I., Barakat, M., Barakat, R., Zobell, B., Cho, W., Chelu, M. G., & Marrouche, N. F. (2020). Smartphone ECG monitoring system helps lower emergency room and clinic visits in post-atrial fibrillation ablation patients.  Clinical Medicine Insights: Cardiology, 14, 1-7. https://doi.org/10.1177/1179546820901508

Brandes, A., Stavrakis, S., Freedman, B., Antoniou, S., Boriani, G., Camm, A. J., Chow, C. K., Ding, E., Engdahl, J., Gibson, M. M., Golovchiner, G., Glotzer, T., Guo, Y., Healey, J. S., Hills, M. T., Johnson, L., Lip, G. Y. H., Lobban, T., Macfarlane, P. W., ... Turakhia, M. P. (2022). Consumer-led screening for atrial fibrillation: Frontier review of the AF-SCREEN international collaboration.  Circulation, 146(1461-1474). https://doi.org/10.1161/CIRCULATIONAHA.121.058911

Centers for Disease Control and Prevention. (2024). About atrial fibrillation.  CDC Heart Disease and Stroke Prevention.Retrieved from  https://www.cdc.gov/heart-disease/about/atrial-fibrillation.html

Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., Gorenek, B., Hess, P. L., Hlatky, M., Hogan, G., Ibeh, C., Indik, J. H., Kido, K., Kusumoto, F., Link, M. S., ... Van Wagoner, D. R. (2023). 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation.  Journal of the American College of Cardiology, 83(1), 109-279. https://doi.org/10.1016/j.jacc.2023.08.017

Khurshid, S., Ashburner, J. M., Ellinor, P. T., McManus, D. D., Atlas, S. J., Singer, D. E., & Lubitz, S. A. (2023). Prevalence and incidence of atrial fibrillation among older primary care patients.  JAMA Network Open, 6(2), e2255838. https://doi.org/10.1001/jamanetworkopen.2022.55838

Kornej, J., Börschel, C. S., Benjamin, E. J., & Schnabel, R. B. (2020). Epidemiology of atrial fibrillation in the 21st century.  Circulation Research, 127(4), 4-20.  https://doi.org/10.1161/CIRCRESAHA.120.316340

Pearson, V. (2022). Mobile ECG monitoring for atrial fibrillation management: A literature review.  International Journal of Advanced Health Science and Technology, 2(1), 19-25.  https://doi.org/10.35882/ijahst.v2i1.4

5

Atrial Fibrillation and Portable ECG in Diagnosis and Monitoring

Name of Student

Lecturer Name

Course

Date

Atrial Fibrillation and Portable ECG in Diagnosis and Monitoring

Introduction

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, affects millions of people and is an important cause of morbidity and mortality. The adult population, particularly those over 65, faces an increasing prevalence of AF due to aging, comorbidities, and lifestyle factors. AF increases the risk of stroke, heart failure and additional cardiovascular complications greatly and early detection of AF is imperative in reducing its risk. AF also carries a significant health and economic burden for other than individual health. For the sake of the improvement of patient outcomes, effective diagnosis and a continuous monitoring have to be achieved and that is achievable through the use of the technology such as the portable electrocardiogram (ECG) devices. This paper describes the global AF burden, AF clinical presentation and the paradigm shift in healthcare technology enabled by the advent of portable ECG devices assessing their impact on patient outcomes.

Global Burden of Disease Condition

Atrial fibrillation is a growing public health issue with increasing worldwide prevalence and incidence. AF affects over 46 million people worldwide according to the Global Burden of Disease study, and it is projected to increase with aging and prevalence of risk factors (Kornej et al., 2020). It is estimated that, in the US alone, the number of people who have AF will be 12.1 million by 2030 (CDC, 2024). AF is more likely to develop in older individuals with 6.4% prevalence at age 65–69 and 28.5% in those above 85 years (Khurshid et al., 2023). Additionally, AF is associated with increased healthcare utilization in the form of increased rates of hospitalization, emergency room visits, and an increased risk of ischemic stroke (Joglar et al., 2023).

AF has a wide range of clinical presentation from asymptomatic to severe with palpitations, dyspnea, fatigue, dizziness, chest pain (CDC, 2024). Most episodes are paroxysmal, many of which are not detected and so are missed or delayed diagnosis leading to an enhanced risk of complication thromboembolism. However, intermittent, often asymptomatic presentations often require prolonged rhythm monitoring that places it as the gold standard for diagnosis. According to current guidelines, stroke risk stratification should use the CHA2DS2-VASc score and anticoagulation therapy for high risk patients (Joglar et al., 2023). Treatment options include rate and rhythm control with medications including beta blockers, electrical cardioversion and catheter ablation, and lifestyle modifications. However, there is a lack of timely and effective monitoring; and technological innovation is needed to facilitate improved detection and management of the disease.

Technology and Healthcare

The introduction of digital health technologies has shaped the healthcare in a great way. Portable ECG devices are great examples of the shift toward patient centered care as they enable real time monitoring, early detection and improved disease management. Because the devices are so capable of detecting AF outside of traditional clinical settings, patients with intermittent arrhythmias who would otherwise go undiagnosed are of particular relevance (Brandes et al., 2022). This aligns with the broader movement of digital medicine through the shift towards wearable and mobile health technologies which allow for continuous monitoring for the purposes of developing personalized treatment plans and proactive interventions.

There are a number of benefits of integrating portable ECGs into clinical practice, such as increased diagnostic yield, improved patient engagement, and possible cost savings from decreased hospitalizations and emergency visits (Aljuaid et al., 2020). However, there remains doubt about the accuracy, reliability and interpretation of consumer-driven ECG readings from the public. While some AF studies have reported high sensitivity and specificity in detecting AF, challenges including false positives, the need for physician confirmation, and integration with electronic health records remain (Brandes et al., 2022). Complicating further widespread adoption are regulatory oversight, data privacy concerns, as well as disparities in access to technology. However, portable ECGs are increasingly used as an important asset of AF management, along with traditional diagnostic techniques and to improve patient outcomes.

Chosen Evidence-Based Technology Use in Disease

Portable ECG devices have shown a great deal of potential for improving detection and monitoring of AF. Real time rhythm assessment ECG devices incorporate single or multi lead ECG technology with incorporated smartphone apps. Research have indicated that the portable ECGs, like KardiaMobile and Apple Watch, have high sensitivity (96%) and specificity (92%) in detecting AF (Pearson 2022). The devices enable on demand ECG recording whereby patients can record arrhythmic episodes when they happen for improved diagnostic accuracy compared to regular intermittent monitoring.

Portable ECG use has been linked to better clinical outcomes including fewer emergency department visits and hospitalizations. Aljuaid et al. (2020) found that patients using smartphone based ECG monitor in comparison to the patients relying on traditional event monitor have significantly fewer clinic visits and emergency room admissions. In addition, the ability to perform continuous remote monitoring allows for timely correction of anticoagulation and antirrythmic therapy and eliminates the risk of stroke and of complications of AF (Joglar et al., 2023). Portable ECG technology is thus transformative: its ability to enable real-time data, that leads to the potential to intervene early and with personalized treatment, is a major advance in this area.

Despite these advantages, limitations exist. This could lead to unnecessary anxiety and excessive healthcare utilization through false positives. Workflow difficulties in clinical practice arise from the need for physician confirmation of automated interpretations. Further, there may be cost and accessibility issues that impact widespread adoption, especially with socioeconomically disadvantaged populations (Brandes et al., 2022). In order to address these barriers, healthcare providers, technology developers and policymakers must work together to ensure that implementation is optimized and benefits are maximized.

Conclusion

Atrial fibrillation is a major source of global health burden, and particularly so among the aging adult population. The ability to detect and monitor continuously is crucial for reducing complications and enhancing patient outcomes. AF diagnosis and management has been contributed by portable ECG technology, a useful tool for real-time rhythm assessment, early detection and remote monitoring. These devices provide great advantages but these devices still have to address challenges of accuracy, integration into clinical workflows and accessibility. In the coming years, the future of arrhythmia care will be shaped in large part by the continued advancement of digital health technologies and their incorporation into guideline based AF management. By combining portables ECGs with the standard monitoring approach, AF detection can be further improved, optimal treatment can be achieved, and disease burden can be reduced.

References

Aljuaid, M., Marashly, Q., AlDanaf, J., Tawhari, I., Barakat, M., Barakat, R., Zobell, B., Cho, W., Chelu, M. G., & Marrouche, N. F. (2020). Smartphone ECG monitoring system helps lower emergency room and clinic visits in post-atrial fibrillation ablation patients.  Clinical Medicine Insights: Cardiology, 14, 1-7. https://doi.org/10.1177/1179546820901508

Brandes, A., Stavrakis, S., Freedman, B., Antoniou, S., Boriani, G., Camm, A. J., Chow, C. K., Ding, E., Engdahl, J., Gibson, M. M., Golovchiner, G., Glotzer, T., Guo, Y., Healey, J. S., Hills, M. T., Johnson, L., Lip, G. Y. H., Lobban, T., Macfarlane, P. W., ... Turakhia, M. P. (2022). Consumer-led screening for atrial fibrillation: Frontier review of the AF-SCREEN international collaboration.  Circulation, 146(1461-1474). https://doi.org/10.1161/CIRCULATIONAHA.121.058911

Centers for Disease Control and Prevention. (2024). About atrial fibrillation.  CDC Heart Disease and Stroke Prevention.Retrieved from  https://www.cdc.gov/heart-disease/about/atrial-fibrillation.html

Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., Gorenek, B., Hess, P. L., Hlatky, M., Hogan, G., Ibeh, C., Indik, J. H., Kido, K., Kusumoto, F., Link, M. S., ... Van Wagoner, D. R. (2023). 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation.  Journal of the American College of Cardiology, 83(1), 109-279. https://doi.org/10.1016/j.jacc.2023.08.017

Khurshid, S., Ashburner, J. M., Ellinor, P. T., McManus, D. D., Atlas, S. J., Singer, D. E., & Lubitz, S. A. (2023). Prevalence and incidence of atrial fibrillation among older primary care patients.  JAMA Network Open, 6(2), e2255838. https://doi.org/10.1001/jamanetworkopen.2022.55838

Kornej, J., Börschel, C. S., Benjamin, E. J., & Schnabel, R. B. (2020). Epidemiology of atrial fibrillation in the 21st century.  Circulation Research, 127(4), 4-20.  https://doi.org/10.1161/CIRCRESAHA.120.316340

Pearson, V. (2022). Mobile ECG monitoring for atrial fibrillation management: A literature review.  International Journal of Advanced Health Science and Technology, 2(1), 19-25.  https://doi.org/10.35882/ijahst.v2i1.4